본문 바로가기
  • Home

Effect of Sharbat Afsantīn in Poly Cystic Ovarian Disease - An Open Observational Study

  • CELLMED
  • Abbr : CellMed
  • 2022, 12(3), pp.10-10
  • DOI : 10.5667/CellMed.2022.010
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : June 2, 2022
  • Accepted : August 24, 2022
  • Published : August 31, 2022

Zainab Zubair 1 Ismath Shameem 2 Wajeeha Begum 3

1Dept. of Ilmul Qabalat wa Amraze Niswan, National Institute of Unani Medicine
2National Institute of Unani Medicine
3NIUM

Accredited

ABSTRACT

Objective: The objective of the study was to evaluate the effect of Sharbat Afsantīn in Polycystic Ovarian Disease. Methods: An open observational study was carried out in the Department of Ilmul Qabalat wa Amraze Niswan. Diagnosed cases(n=30) of PCOD were included in the study. Patients with thyroid dysfunction, systemic diseases, on hormonal treatment in last three months, pregnancy and lactation were excluded. Research drug (Sharbat Afsantīn) was administered orally in a dose of 25ml twice daily for 15 days/cycle for three consecutive cycles. Outcome measures were, changes in subjective parameters (duration of cycle, duration and amount of flow and weight reduction) and objective parameters {pictorial blood loss assessment chart (PBAC) score, basal metabolic index (BMI), modified Ferriman Gallwey (mFG) score, acanthosis nigricans scale and pelvic ultrasonography}. Data were analyzed using paired Student ‘t’ test. Results: Changes in duration of cycle, duration and amount of flow were achieved in 83.3%, 50% and 40% patients respectively and weight reduction in 30% patients. Changes in PBAC score and BMI were achieved in 50% and 30% patients respectively and 30% patients showed normal findings on pelvic ultrasonography. Conclusion: Sharbat Afsantīn can be used as an alternate remedy in PCOD patients, as it has significant effect to regularize menstruation by reduction in BMI and probably by improving insulin resistance in PCOD. No adverse effect of Sharbat Afsantīn was noted during the trial.

Citation status

* References for papers published after 2022 are currently being built.